Clinical intelligence

Selectable illustrative cases; simulated decision support, not validated diagnosis or prescribing.

Illustrative experience; not a live service. All case details are illustrative. This is not medical advice and must not be used for patient care.

Historical antibiogram reference

Antibiogram Intelligence

Historical laboratory evidence · 2023 / 2024

King Abdulaziz Medical City — Riyadh · Ministry of National Guard Health Affairs

Reported isolates, not patient cases. Not live or national surveillance. S = susceptible; I = intermediate (including the colistin column). Missing values are not zero. No pooled percentages, inferred resistance or validated AI claims.

Educational reference only. Population-level susceptibility cannot prescribe treatment for an individual patient; use current laboratory findings and professional stewardship review.

2023 · All hospital departments

Reported organism rows; counts are not summed across overlapping departments.

Escherichia coli: 6,221 isolates · p.8
Klebsiella sp: 3,556 isolates · p.8
Pseudomonas sp: 2,432 isolates · p.8

Original report 2023

2024 · All hospital departments

Reported organism rows; counts are not summed across overlapping departments.

Escherichia coli: 6,743 isolates · p.1
Klebsiella sp: 3,919 isolates · p.1
Pseudomonas sp: 2,842 isolates · p.1

Original report 2024

Connected illustrative scenario

Riyadh · Klebsiella pneumoniae

Days 1–9 · illustrative reporting cycle · 7 ICU isolates; association does not prove transmission.

Patient factors requiring professional review: renal function, allergies, infection severity, prior antibiotics and specimen quality. The simulated susceptibility profile is not a treatment recommendation.

Case

Case ID

CASE-EXAMPLE-0041

Patient

Example clinical case — 64-year-old male (illustrative record)

Context

Day 6 of admission, medical ICU

Specimen

Blood culture, drawn Day 4

Organism

Klebsiella pneumoniae

Multidrug-resistant

Carbapenemase-producing (OXA-48-like, illustrative annotation)

Treatment information (reference only)

Local illustrative guideline lists ceftazidime–avibactam as a reference option for OXA-48-like producers.

Aminoglycoside combination is shown as an illustrative alternative in this concept dataset.

Infection-prevention contact precautions flagged for this illustrative case.

Resistance profile

Antimicrobial	Result
Meropenem	Resistant
Ceftazidime–avibactam	Susceptible
Amikacin	Susceptible
Ciprofloxacin	Resistant
Colistin	Susceptible
Piperacillin–tazobactam	Resistant

Illustrative experience; not a live service. All case details are illustrative. This is not medical advice and must not be used for patient care.